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Abstract
Background: The involvement of the cyclooxygenases (COX), in particular COX-2, is well documented for
many tumours, e.g. colon, breast and prostate cancer, by both experimental and clinical studies. There are
epidemiological data from subjects using NSAIDs, and experimental evidence supporting the hypothesis of
prostaglandins (PGs) as regulators of tumourigenesis in the ovary. One of the end products of PG-synthesis, PGE2,
regulates several key-processes, which are characteristic for tumour growth, e.g. angiogenesis, proliferation and
apoptosisis. The present study investigated the pathway for PGE2  – synthesis and signalling in ovarian
tumourigenesis by analysing specimen from normal ovaries (n = 18), benign (B) (n = 8), borderline type (BL) (n =
6) and malignant tumours (AC) (n = 22). The expression and cell-specific localization of COX-1, COX-2,
microsomal prostaglandin E synthase-1 (mPGES-1) and two of the receptors for PGE2, EP1 and EP2, were
examined by immunoblotting (IB) and immunohistochemistry (IHC).
Results: The results are in line with earlier studies demonstrating an increase of COX-2 in AC compared to the
normal ovary, B and BL tumours. Increased expressions were also observed for COX-1, mPGES-1 and EP-1 which
all were significantly (p < 0.05) augmented in less differentiated AC (grades: moderately-, poorly- and
undifferentiated). The increase of COX-2 was also correlated to stage (FIGO classification) with significant
elevations in stages II and III. EP1 was increased in stage III while no significant alterations were demonstrated for
COX-1, mPGES-1 or EP2 for stage. IHC revealed staining of the tumour cells, but also increase of COX-1, COX-
2, mPGES-1 and EP1–2 in the stromal compartment of AC (grades: moderately-, poorly- and undifferentiated). This
observation suggests interactions between tumour cells and stromal cells (fibroblasts, immune cells), e.g.
paracrine signalling mediated by growth factors, cytokines and possibly PGs.
Conclusion: The increases of COX-1, COX-2, mPGES-1 and EP1–2 in epithelial ovarian cancer, supports the
hypothesis that PGE2-synthesis and signalling are of importance for malignant transformation and progression.
The observed augmentations of COX-1, COX-2 and mPGES-1 have implications for future therapeutic strategies.
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Background
Epithelial ovarian cancer (EOC), which compromises
90% of all ovarian malignancies, is the leading cause of
death from gynaecological cancer in the western world
[1]. The pathology underlying this disease is not fully
understood, but an inflammatory process is one factor
suggested to participate in tumourigenesis [2]. Chronic
inflammatory conditions caused by talc or asbestos expo-
sure, endometriosis or other pelvic inflammatory diseases
are related to an increased incidence of EOC [3]. Several
classical mediators of inflammation participate in the
ovulatory process, proposing each ovulation to have
resemblance with a localized inflammatory reaction [4].
The importance of inflammation/ovulation in ovarian
tumourigenesis is further supported by the observed
reduction in the relative risk to develop EOC in women
with a decrease in the total number of ovulations during
a lifetime, i.e. due to childbearing or the use of contracep-
tive pills [5]. This was already suggested three decades ago
by Fathalla [6] as the "incessant ovulation hypothesis".
Tubal ligation and hysterectomy without oophorectomy,
which reduces local inflammation, also decreased the risk
to develop EOC, while inflammatory conditions in the
pelvis, e.g. endometriosis, were associated with increased
risk of EOC [5].
A measure to evaluate the role of inflammation in
tumourigenesis is to examine the correlation between the
use of non-steroidal anti-inflammatory drugs (NSAIDs)
and the risk to develop cancer. The use of NSAIDs or aspi-
rin causes a reduction in the risk to develop colorectal-
(CRC) and to a less extent, prostate- and breast cancer [7].
Inconsistent results have been published for EOC, but sev-
eral studies suggest an inverse relationship between the
use of NSAIDs and the incidence of this malignancy [8].
Several in vivo [9] and in vitro [10-13] experiments have
demonstrated reduced tumour growth [9], decreased pro-
liferation [11], cell cycle arrest [10], attenuated metallo-
protease-dependent motility and invasive activity [13],
and reduced expression of vascular endothelial growth
factor expression [14] by NSAIDs in models for EOC.
COX-1 and COX-2 are key enzymes in the synthesis of
prostanoids by converting arachidonic acid to PGG2 and
subsequently to PGH2 [15]. PGE2 is derived from PGH2 by
a synthase, prostaglandin E synthase (PGES). Three iso-
forms of PGES have been identified, microsomal prostag-
landin E synthase (mPGES-1 and mPGES-2) and cytosolic
PGES (p23) [15]. Prostaglandin E2 (PGE2) was implicated
in tumour progression [15] and increased contents of
prostanoids (PGE2 and TxB2) in ovarian tumours have
been described [16,17]. Later studies have reported PGE2
as a regulator of proliferation and apoptosis in ovarian
cancer cell lines [18]. Several reports have shown that
either COX-1 or COX-2 is up-regulated in EOC [14,19-
21]. Ovarian tumours with increased content of COX-2
were associated with chemotherapy resistance and poor
prognosis [22] while COX-1 was suggested to participate
in neo-vascularization [14].
PGE2 is ligand for at least four membrane-bound recep-
tors, EP1–4. EP2 was induced in colon polyps in mice with
a targeted deletion of the adenomatosis polyposis coli
(APC) gene [23] and this receptor has also a key role in the
ovulatory process [24]. Studies in EP1 receptor knockout
mice and experiments with selective receptor antagonists,
have demonstrated a role for this receptor in colon and
breast carcinogenesis [25]. PGE2 is produced by a variety
of cells and has a broad range of effects in individual cells
and organs.
We choosed to analyse the rate-limiting enzymes (COX-1,
COX-2 and mPGES-1) for PGE2-synthesis and two of its
receptors (EP1–2) in specimen from normal ovaries and
from epithelial ovarian tumours of different grades and
stages, as an approach to delineate the role for PGE2 in
ovarian tumorigenesis, since the prostanoid itself is
quickly redistributed and degraded in whole tissue biop-
sies. Furthermore, the combined techniques of immuno-
blotting and immunohistochemistry allowed us to
determine the contents as well as the cell-specific localiza-
tions of the individual proteins. The cell- and stage spe-
cific increases of COX-1, COX-2, mPGES-1 and EP1–2,
support the hypothesis that PGE2-synthesis and signalling
are of importance for malignant transformation and pro-
gression in EOC. The observed augmentations of PGE2-
signalling capacity have implications for future therapies.
Materials and methods
Human tissues
Biopsies from normal human ovaries were obtained from
18 women undergoing laparotomy or laparoscopy for
non- ovarian diseases/benign pelvic conditions. Ovarian
epithelial tumours tissues were obtained from 36 women
(approved by the Ethics Committee of the Medical Fac-
ulty, Göteborg University) (Table 1). Tissues were imme-
diately washed in ice-cold saline, snap-frozen in liquid
nitrogen and stored at -70°C until analysis [26,27]. All
samples were examined by an experienced pathologist
and classified according to FIGO for diagnosis.
Immunoblotting
Soluble tissue extracts were prepared from 45 tissue biop-
sies (Table 1), and immunoblotting was performed as pre-
viously described [26,27]. Thirty-five µg of total protein
was loaded into each well for 1D SDS PAGE (4–12% Bis-
Tris NuPage gels, Invitrogen, Paisley, UK). The blotting-
membranes were incubated with blocking buffer contain-
ing the following primary antibodies from Cayman
Chemical Co. (Ann Arbor, MI, USA): COX-1 (cat. no.Molecular Cancer 2006, 5:62 http://www.molecular-cancer.com/content/5/1/62
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160110, monoclonal, dilution 1:1,000), COX-2 (cat. no.
160126, rabbit polyclonal, dilution 1:1,000), mPGES-1
(cat. no. 160140, rabbit polyclonal, dilution 1:500), EP1
receptor (cat. no. 101740, rabbit polyclonal, dilution
1:500) and EP2 receptor (cat. no. 101750, rabbit polyclo-
nal, dilution 1:500). COX-1 and COX-2 electrophoresis
standards from Cayman Chemical Co. (cat. no. 360100,
360120) were used as positive controls. The specificity of
the COX-2 antibody was verified by the addition of a
blocking peptide to the antibody solution prior to immu-
nodetection (Cayman Chemical Co,. cat. no. 360106).
Ovaries obtained from immature rats stimulated with
pregnant mare serum gonadotrophin (PMSG) and human
chorionic gonadotropin (hCG), (preovulatory ovaries)
were used as positive control for mPGES-1 and EP1–2.
Immunoreactive proteins were visualized by chemilumi-
nescence using alkaline-phosphatase-conjugated second-
ary goat anti-mouse or goat anti-rabbit antibodies
(dilution 1:40 000), and the CDP-Star® substrate (Tropix,
Bedford, UK). The conditions were kept constant during
the analysis of the immunoblots and each blot contained
an internal control sample (see below and Figure legend 1
for details) in order to compare the levels of expression
between blots [26,27].
Immunohistochemistry
Frozen biopsies from 18 normal ovaries and ovarian
tumours (Table 1) were cryosectioned (5–7 µm) and
mounted on electrically charged glass slides, fixed in cold
acetone at -20°C for 10 min and air dried in room temper-
ature. The endogenous peroxidase activity was blocked by
treatment for 4 min with peroxidase block from DAKO
EnVision™+System, Peroxidase (AEC) kit (DAKO Corpo-
ration, USA). Primary antibodies against COX-1 (1:100),
COX-2 (Cayman Chemical Co., cat. no. 160112, mono-
clonal, 1:100), mPGES-1 (1:50), EP1 (1:50) EP2 (1:50)
Table 1: Histological description
Sample no. P-H Sample no. P-H Grade Stage
1N F 2 7 B L S I
2N F 2 8 B L S I B
3N F 2 9 B L S I A
4N F 3 0 B L M I A
5 NF 31 BLM IIB
6N F 3 2 B L M I I
7 NF 33 AS High II
8 NF 34 AM High IB
9 NP 35 AS High/Moderate III
10 NP 36 AS High/Moderate I
11 NP 37 AS Moderate III
12 NP 38 AS Moderate III
13 NP 39 AS Moderate III
14 NP 40 AS Moderate II
15 NP 41 AS Moderate II
16 NP 42 AS Poor III
17 NP 43 AS Poor III
18 NP 44 AS Poor III
19 BS 45 AS Poor III
20 BS 46 AS Poor III
21 BS 47 AS Poor III
22 BS 48 AS Poor III
23 BM 49 AS Poor II
24 BM 50 AS Poor II
25 BM 51 AM Poor III
26 BM 52 AM Poor III
53 AU Undiff III
54 AU Undiff I
Histological description of ovarian tissue including sample numbers which can be found in representative immunoblots and immunohistochemistry 
figures. Abbreviations: P-H; patho-histologic description, NF; normal fertile, NP; normal postmenopausal, BS; benign serous, BM; benign mucinous, 
BLS; borderline type serous, BLM; borderline type mucinous, AS; adenocarcinoma serous, AM; adenocarcinoma mucinous, AU; adenocarcinoma 
undifferentiated type.Molecular Cancer 2006, 5:62 http://www.molecular-cancer.com/content/5/1/62
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and CK8 (1:400) diluted in TBS were applied overnight at
4°C, followed by biotinylated goat anti-mouse immu-
noglobulin (1:60) (VECTASTAIN® ABC kit, Vector Labora-
tories, Inc., Burlingame, CA) for 45 min at 37°C and
finally avidin-biotin-peroxidase complex (VECTASTAIN®
ABC kit, Vector Laboratories) at 37°C for 30 min. The
enzymatic reaction was developed using AEC Chromogen
Substrate Buffer (DAKO EnVision™+System, Peroxidase
(AEC) kit, DAKO). Slides were counterstained with hae-
matoxylin and mounted in 10% glycerol. The mono-
clonal COX-2 antibody used here was evaluated
previously for immunohistochemistry by blocking exper-
iments using a specific peptide [28]. Antibodies against
cytokeratin 8 (CK8) (monoclonal, Low Molecular Weight,
DAKO, Copenhagen, Denmark), was used as a marker for
epithelial cells. Primary antibodies were replaced by equal
amounts of TBS for negative controls. The sections were
viewed in a Nikon microphot FX microscope and photo-
graphed with a Nikon Coolpix 990 digital camera.
Densitometric scanning
Semi-quantitative measurements of proteins from the
immunoblots were made by densitometry (Fluor-S™ Mul-
timager, Quantity One ver. 4.1.0., BioRad, Hercules, CA,
USA). The optical density (OD) of each band was meas-
ured. An ovarian sample was used as an internal standard
on each blot, and the measured value of this sample was
set to 100%. The signal from each band was then com-
pared to the standard and the obtained relative value was
used for statistical analysis [26,27].
Statistics
Values are given as mean ± SEM. ANOVA followed by
Fischer's LSD post-hoc test was used for statistical analysis
of the data obtained by densitometric scanning. A p-value
less than 0.05 was considered to be significant. Data is
presented in a histogram and with a typical immunoblot
of selected samples for each analysed protein.
Results
Increases of COX-1, COX-2, mPGES-1 and EP1 in 
adenocarcinomas
Significant (p < 0.05) increases of COX-1, COX-2,
mPGES-1 and EP1 were demonstrated in the adenocarci-
nomas (AC) in comparison with normal ovarian tissue,
benign adenomas and borderline tumours (B/BL) (Figure
1, 2, 3, 4, 5). EP2 was also increased in comparison to the
B/BL tumours. An increase, although not significant, of
COX-2, was noticed in the B/BL group, compared to spec-
imens from normal ovaries.
To examine if the pattern of expression was influenced by
the degree of differentiation (grade) in the malignant
group of tumours (AC), these tumours were dived into
three groups; i) borderline tumours and highly differenti-
ated AC (BL+H); ii) high/moderately and moderately dif-
ferentiated AC (H/M+M); and iii) poorly differentiated
and undifferentiated AC (P+U). The rationale to include
highly differentiated AC (H) with the borderline (BL) type
tumours was that these tumours are clinically considered
to have more benign prognosis. The expressions of COX-
1, mPGES-1 and EP1 were all significantly elevated in
both the H/M+M and P+U group compared to the more
differentiated tumours in the BL+M group. (Figure 6).
There was also an increase of EP2 in the same groups,
although not significant. COX-2 expression differed
between tumours in the same histological group, but the
majority of the tumours exhibited a strong signal for
Relative protein expressions (mean ± SEM) of COX-1 in nor- mal ovaries (N = pre- and postmenopausal ovaries (n = 10),  BB = benign- and borderline type tumours, (n = 13), and AC  = adenocarcinomas (n = 22) Figure 1
Relative protein expressions (mean ± SEM) of COX-1 in nor-
mal ovaries (N = pre- and postmenopausal ovaries (n = 10), 
BB = benign- and borderline type tumours, (n = 13), and AC 
= adenocarcinomas (n = 22).(a) P < 0.05 vs normal samples 
(N), (b) P < 0.05 vs benign/borderline (BB). The measure-
ments are presented as percentage changes compared to a 
reference sample (tumour tissue). Below each histogram a 
representative immunoblott is presented. Each number cor-
relates to the patho-histological description of the sample 
(see Table 1).
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COX-2 (18/22 of the AC, 21/36 of all tumours), while a
few tumours demonstrated a weak band (4/22 of the AC,
15/36 of all tumours). Amongst the four AC with low lev-
els of expression, one was highly differentiated (H), two
were in the group of high/moderately differentiated (H/
M) and one was moderately differentiated (M). The
expression patterns were further analyzed in the AC
according to FIGO-stage (Figure 7). COX-2 demonstrated
significant increases in both stage II and III cancers, com-
pared to stage I. An increase was also shown for EP1 in
stage III tumours compared to stage I. No differences were
observed for COX-1, mPGES-1 or EP2.
A representative blot from each protein analyzed is pre-
sented in Figure 1, 2, 3, 4, 5. The major band for all the
examined proteins migrated at their expected molecular
weights (Mr). For mPGES-1, EP1, and EP2, additional
bands with higher and lower Mr were observed in the
group of malignant tumours (AC) (Figure 3, 4, 5). The
additional Mr species most likely represents phosphor-
ylated forms of mPGES-1 and EP1–2. However, these
bands for EP1–2 might also represent splice variants of the
receptors [29].
Cell-specific localisation of COX-1, COX-2, mPGES-1, EP1 
and EP2 in the normal ovary
Tissue biopsies from nine normal ovaries were used for
immunohistochemistry. Four of the ovaries were from fer-
tile women and five from post-menopausal women
undergoing surgery for benign non-ovarian diseases. Each
Relative protein expressions (mean ± SEM) of mPGES-1in  normal ovaries (N = pre- and postmenopausal ovaries (n =  10), BB = benign- and borderline type tumours, (n = 13), and  AC = adenocarcinomas (n = 22) Figure 3
Relative protein expressions (mean ± SEM) of mPGES-1in 
normal ovaries (N = pre- and postmenopausal ovaries (n = 
10), BB = benign- and borderline type tumours, (n = 13), and 
AC = adenocarcinomas (n = 22).(a) P < 0.05 vs normal sam-
ples (N), (b) P < 0.05 vs benign/borderline (BB). The meas-
urements are presented as percentage changes compared to 
a reference sample (normal ovarian tissue). Below each his-
togram a representative immunoblott is presented. Each 
number correlates to the patho-histological description of 
the sample (see Table 1).
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Relative protein expressions (mean ± SEM) of COX-2 in nor- mal ovaries (N = pre- and postmenopausal ovaries (n = 10),  BB = benign- and borderline type tumours, (n = 13), and AC  = adenocarcinomas (n = 22) Figure 2
Relative protein expressions (mean ± SEM) of COX-2 in nor-
mal ovaries (N = pre- and postmenopausal ovaries (n = 10), 
BB = benign- and borderline type tumours, (n = 13), and AC 
= adenocarcinomas (n = 22).(a) P < 0.05 vs normal samples 
(N), (b) P < 0.05 vs benign/borderline (BB). The measure-
ments are presented as percentage changes compared to a 
reference sample (normal ovarian tissue). Below each histo-
gram a representative immunoblott is presented. Each 
number correlates to the patho-histological description of 
the sample (see Table 1).
NB BA C
0
100
200
300
400
500
600
700
800
900
a,b
C
O
X
-
2
 
e
x
p
r
e
s
s
i
o
n
,
%
 
o
f
 
i
n
t
e
r
n
a
l
c
o
n
t
r
o
l
NB BA C
0
100
200
300
400
500
600
700
800
900
a,b
C
O
X
-
2
 
e
x
p
r
e
s
s
i
o
n
,
%
 
o
f
 
i
n
t
e
r
n
a
l
c
o
n
t
r
o
l
7
N BB AC
72 kDa kDa
91 01 1 2 2 2 5 3 2 2 93 5 5 2 44 39 46 49
7
N BB AC
72 kDa kDaMolecular Cancer 2006, 5:62 http://www.molecular-cancer.com/content/5/1/62
Page 6 of 12
(page number not for citation purposes)
ovary was consecutively sectioned and stained for cytoker-
atin 8 (CK8), a marker for epithelial cells (Figure 8A, 9A)
and the individual proteins in the PGE2 synthesis- and sig-
nalling pathway. DAPI was used for nuclear staining.
COX-1 was present in both surface epithelial cells (OSE)
and epithelial cells lining the inclusion cysts (Figure 8B,
9C). Some staining was also observed in the stroma (Fig-
ure 8B). The signal for COX-2 in the OSE was negligible.
However, weak staining was noticed in some areas of the
underlying stroma (Figure 8C). An interesting observation
was the clear staining for COX-2 in the epithelial cells of
the inclusion cysts (Figure 9D). Staining for mPGES-1 was
predominantly localized to cells in the stroma. Some of
the epithelial cells on the ovarian surface demonstrated
staining for mPGES-1 (Figure 8D). Both EP1 and EP2 were
expressed in OSE, while only EP2 was present in stroma
cells, an expression pattern similar to that observed for
mPGES-1 (Figure 8E,F).
Cell-specific localisation of COX-1, COX-2, mPGES-1, EP1 
and EP2 in benign, borderline and malignant ovarian 
tumours
Five benign cystadenomas (three serous and two muci-
nous), three BL (two serous and one mucinous), and three
serous ovarian AC (one highly, one moderately and one
poorly differentiated AC) were used for immunohisto-
chemistry (IHC). Serial sections from each tumour were
stained for the expression of COX-1, COX-2, mPGES-1,
EP1 and EP2. CK8 was used as a marker for epithelial
derived cells (Figure 10A, 11A). The results are presented
as representative pictures from a serous borderline type
Relative protein expressions (mean ± SEM) of EP2 in normal  ovaries (N = pre- and postmenopausal ovaries (n = 10), BB =  benign- and borderline type tumours, (n = 13), and AC =  adenocarcinomas (n = 22) Figure 5
Relative protein expressions (mean ± SEM) of EP2 in normal 
ovaries (N = pre- and postmenopausal ovaries (n = 10), BB = 
benign- and borderline type tumours, (n = 13), and AC = 
adenocarcinomas (n = 22).(b) P < 0.05 vs benign/borderline 
(BB). The measurements are presented as percentage 
changes compared to a reference sample (normal ovarian tis-
sue). Below each histogram a representative immunoblott is 
presented. Each number correlates to the patho-histological 
description of the sample (see Table 1).
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Relative protein expressions (mean ± SEM) of EP1 in normal 
ovaries (N = pre- and postmenopausal ovaries (n = 10), BB = 
benign- and borderline type tumours, (n = 13), and AC = 
adenocarcinomas (n = 22).(a) P < 0.05 vs normal samples 
(N), (b) P < 0.05 vs benign/borderline (BB). The measure-
ments are presented as percentage changes compared to a 
reference sample (rat preovulatory ovary). Below each histo-
gram a representative immunoblott is presented. Each 
number correlates to the patho-histological description of 
the sample (see Table 1).
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Relative expressions (mean ± SEM) of COX-1, COX-2,  mPGES-1, EP1 and EP2 Figure 6
Relative expressions (mean ± SEM) of COX-1, COX-2, mPGES-1, 
EP1 and EP2. Tissue contents in tumours related to grade of differ-
entiation. (BL+H = borderline type tumours and highly differenti-
ated tumours (n = 8), H/M+M = highly to moderately, and 
moderately differentiated tumours (n = 7), P+U = poorly and un-
differentiated tumours (n = 13).(a) P < 0.05 vs borderline type 
tumours and highly differentiated tumours (B/BL), (b) P < 0.05 vs 
highly to moderately and moderately differentiated tumours (H/
M+M).
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Relative expressions (mean ± SEM) of COX-1, COX-2,  mPGES-1, EP1 and EP2 Figure 7
Relative expressions (mean ± SEM) of COX-1, COX-2, mPGES-1, 
EP1 and EP2. Tissue contents in malignant tumours (adenocarcino-
mas) related to stage. Stage I (n = 7), stage II (n = 6) and stage III 
(n = 14).(a) P < 0.05 vs stage I, (b) P < 0.05 vs stage II.
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tumour (stage I, Figure 10A–F) and a poorly differentiated
serous AC (stage II, Figure 11A–F).
Distinct staining of COX-1 was demonstrated mainly in
the epithelial cells of the BL tumour (Figure 10B). COX-2
exhibited an even more epithelial concentrated staining
compared to COX-1 (Figure 10C). Both COX-1 and COX-
2 was confined to the cytoplasm of the epithelial cells
(inserts, Figure 10B–C). Microsomal PGES-1 was
expressed predominantly in epithelial cells, but to some
degree also in the stroma, although the staining was much
less homogenous compared to COX-1 and COX-2 (Figure
10D). EP1 and EP2 demonstrated almost identical staining
patterns with both receptors localised to the epithelial
cells of the tumour (Figure 10E,F).
The staining pattern for the AC was different compared to
that of the BL tumours. One exception was COX-1, which
was still predominantly localised to the epithelial cells,
some expression was also present in the stroma (Figure
11B). An increased stromal content was also noticed for
COX-2 (Figure 11C). Intense staining was observed for
mPGES-1, EP1 and EP2 in clusters of tumour cells (Figure
1111D–F).
Discussion
Numerous experimental models have convincingly dem-
onstrated that the increased production of PGE2 in various
tumours, including EOC, is involved in tumorigenesis
[19]. The reduced incidence of tumours by NSAIDs, as
shown in epidemiological studies, supports the concept of
the PGE2 signalling pathway as an important factor in
tumour formation and growth [7]. The present study
demonstrates, for the first time, increased contents and
cell-specific localisation of mPGES-1 and the PGE2 recep-
tors EP1–2 in EOC of different grades and stages compared
to normal ovaries. The study also confirms the earlier
demonstrated expression patterns of COX-1 [14,21] and
COX-2 in EOC [19].
The ovulatory process exhibits several signs related to an
inflammatory reaction, e.g. hyperaemia, extravasation of
leukocytes, proteolytic- and collagenolytic activity [4,30].
One of the key mediators in inflammation, the prosta-
noids, are also released during ovulation from the ovulat-
ing follicle and surrounding ovarian stroma, together with
other autocrine/paracrine factors [31]. In the human
ovary, COX-2 is present in the ovulating follicle during the
preovulatory phase, followed by interstitial localisation of
the enzyme after ovulation [32]. These prostanoids, in
particular PGE2, are thought to contribute to proliferation
and repair of OSE at the site of rupture, in addition to their
crucial role(s) in the intrafollicular regulation of the ovu-
latory process [30]. Repetitive trauma to the epithelial cell
surface, followed by exposure to mitogenic factors, is sug-
gested to be an initiating event in ovarian tumourigenesis
[6,31]. When the EOC was established, elevated levels of
the prostacyclins (PGI2) and tromboxane (TxA2) in
plasma, as well as increased tumour contents of PGE2 and
TxB2  were reported [16,17]. Furthermore, ovarian
tumours with high tissue contents of PGE2, PGF2α and 6-
keto-PGF1α demonstrated a reduced response to chemo-
therapy [33].
COX-1 is constitutively expressed and plays a "housekeep-
ing role" in many cells and has previously been demon-Molecular Cancer 2006, 5:62 http://www.molecular-cancer.com/content/5/1/62
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strated in normal OSE and in inclusion cysts [34] which
are in line with the results of the present study. Further-
more, the contents of COX-1 was unaltered in the group
of benign and borderline type tumours compared to nor-
mal ovaries, and the cellular localisation remained con-
fined to the epithelial cells of these tumours. An increase
of COX-1 was significant in the malignant tumours, but
only in the less differentiated groups (H/M+M and P+U).
COX-1 staining was no longer limited to the epithelial
tumour cells since localisation to the underlying stroma
also was observed. No correlation was found between
FIGO stage and COX-1. Earlier studies have also reported
an increase of COX-1 at both the mRNA and protein levels
in EOC [14]. A stimulatory effect on neo-vascularisation
was proposed since a correlation was demonstrated
between COX-1 expression and the expressions of ang-
iogenic factors (VEGF, HIF-1α, Flk1) [14]. Studies by
Spinella and coworkers [12] demonstrated that endothe-
lin (ET-1) increased COX-1 in ovarian carcinoma cells in
vitro. Since ET-1 is known regulator of VEGF, this effect
might be mediated by COX-1/PGE2 in these cells. Interest-
ingly, several studies on ovarian cancer cell lines have
emphasised the contribution of COX-1 to ovarian
tumourigenesis. In fact, COX-1 was the predominant iso-
form reported to be expressed [20,34,35]. A recent study
[9] used mouse EOC cells (deletion of p53, or overexpres-
sion of c-myc/K-ras or c-myc/Akt) to demonstrate
increased expression of COX-1 in these genetically engi-
neered EOC cells. The conclusion, in accordance with the
study by Kino and co-workers [35], was that COX-1 is the
major regulator of PGE2 synthesis in vitro.
The observation in the present study of COX-2 as more or
less absent from normal OSE confirms results reported
earlier [21,34,36,37]. A clear staining for COX-2 was first
observed in the inclusion cysts, and some, although not
significant, elevation was noticed in the B/BL group. Li et
al. [34] reported a significantly higher expression level of
COX-2 in BL compared to benign tumours (B). The
majority of the analysed (by IHC) tumours in their mate-
rial were BL (69 BL, 18 B and 27 AC), which potentially
influenced their results. They found, however, that the
content was lower in BL compared to AC, which is in line
with the present study. The AC demonstrated a clear ele-
vation of COX-2, in particular in tumours of lower grades
(H/M+M, P+U) in the present study. In contrast to COX-
1, a significant difference with elevated levels of COX-2
Immunohistochemical analysis of normal ovaries Figure 8
Immunohistochemical analysis of normal ovaries; (a-f) Post-
menopausal ovary with surface epithelium; stained with anti-
bodies against CK8 (a); COX-1 (b); COX-2 (c); mPGES-1 
(d);EP1 (e); EP2 (f). Arrow = epithelial cells, Star = stroma cells. 
(Original magnification ×200, inserted pictures X400).
Immunohistochemical analysis of normal ovaries Figure 9
Immunohistochemical analysis of normal ovaries; (a-d)Pre-
menopausal ovary with epithelial cells lining an inclusion cyst; 
stained with antibodies against CK8 (a); COX-1 (c); COX-2 
(d); negative control (b). Arrow = epithelial cells, Star = 
stroma cells. (Original magnification X200, inserted pictures 
×400).Molecular Cancer 2006, 5:62 http://www.molecular-cancer.com/content/5/1/62
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was also found for later stages of tumours (stages II-III).
To our knowledge, this study is the first to quantify the
COX-2 protein expression by immunoblotting in ovarian
tumours. Several earlier studies have shown by IHC that
COX-2 is up-regulated in ovarian neoplasm using differ-
ent scoring systems of staining intensity [20]. Our results
confirm the IHC data on COX-2 shown by others. The
observed increase of COX-2 expression in EOC was corre-
lated to poor differentiation, shorter time to tumour pro-
gression, resistance to chemotherapy, poor prognosis and
significantly shorter survival time compared to patients
with tumours staining negative for COX-2 [22,36,38],
suggesting COX-2 to be an independent prognostic factor
[36]. COX-2 expression was also significantly correlated
with microvessel density and/or VEGF expression in
advanced-stage ovarian serous carcinoma [37,39,40]. In
our study, absence of or weak COX-2 expression was
noticed in the majority of the B/BL tumours and in only
four AC, all of them of high to moderately differentiated
grades, and presumably better prognosis.A recent study
describing positive COX-2 staining of preneoplastic OSE
adjacent to COX-2 negative neoplastic cells, presumably
of higher grades [41], supports our findings. A correlation
to histological subtype was not found for COX-2 in the
present study. The cell-specific localisation of COX-2 in
the B/BL group was almost exclusive in the epithelial cell,
similar to that of COX-1.
Interestingly, both COX-1 and COX-2 were expressed in
OSE lining inclusion cysts in the present study. This obser-
vation might suggest that the appearance of COX-2 in
these cells is an early sign of an altered phenotype (mes-
othelial to epithelial transition, [31]) with malignant
potential. We have previously shown that the expressions
of the adhesion molecules E-cadherin [42,43] and clau-
din-3/4 [27] and the transcription factor C/EBPβ[44] cor-
related with malignancy in EOC. These proteins were also
expressed in epithelial cells of inclusion cysts. Notably,
the expression of C/EBPβ is a putative requirement for the
regulation of COX-2 expression[45]. Li and co-workers
[34] reported also the expression of COX-1 in OSE and
inclusion cysts of the normal ovary, but both these two
locations lacked COX-2 expression. Interestingly, in two
independent studies COX-2 was not expressed in any of
Immunohistochemical analysis of ovarian tumours; Serous  adenocarcinoma, poorly differentiated, stage II (a-f) Figure 11
Immunohistochemical analysis of ovarian tumours; Serous 
adenocarcinoma, poorly differentiated, stage II (a-f). Staining 
with antibodies against CK8 (a); COX-1 (b); COX-2 (c); 
mPGES-1 (d);EP1 (e); EP2 (f). Arrow = epithelial cells, Star = 
stroma cells. (Original magnification ×200, inserted pictures 
×400).
Immunohistochemical analysis of ovarian tumours; Serous  borderline type tumour, stage I (a-f); Figure 10
Immunohistochemical analysis of ovarian tumours; Serous 
borderline type tumour, stage I (a-f); Staining with antibodies 
against CK8 (a); COX-1 (b); COX-2 (c); mPGES-1 (d);EP1 
(e); EP2 (f). Arrow = epithelial cells, Star = stroma cells. (Orig-
inal magnification ×200, inserted pictures ×400).Molecular Cancer 2006, 5:62 http://www.molecular-cancer.com/content/5/1/62
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the ovarian cancer cell lines used(nine [34] and five [41]),
although Denkert and co-workers [36] showed such
expression in cell lines included in their study. The differ-
ence in COX-2 expression in cell-lines and tissue/tumour
biopsies is further strengthened since positive COX-2
staining was more often found at the advancing margin of
tumour invasion and new metastatic lesion [34]. An
explanation to the findings of ovarian cancer cells in cell
culture, not expressing COX-2, can be that cell lines are
devoid of their basement membranes as well as the sur-
rounding and supporting stroma cells. Recent studies
have demonstrated important roles for stromal cells in
tumourigenesis [46]. An autocrine- paracrine regulatory
pathway was described for breast carcinoma and sur-
rounding stromal cells, involving growth factors and
cytokines [46]. Zhou and co-workers [47] demonstrated
that stromal-epithelial interactions resulted in induction
of C/EBPβ in malignant breast epithelial cells. One possi-
bility is therefore that the expression of COX-2 in early
stages of cellular transformation, e.g. in inclusion cyst for-
mation, might be initiated by paracrine factors produced
by the stromal cells, resulting in increased transcription,
e.g. induced by C/EBPβ, of the cox2 gene. The cox2 promo-
tor has previously been suggested to be of potential value
for gene therapy in EOC, due to its tumour-specific activa-
tion in ovarian cancer cell lines in vitro [48]. Furthermore,
studies on ovaries from women undergoing prophylactic
oophorectomy (due to mutations in BRCA1, BRCA2,
MSH1 or MLH1) demonstrated that the increase of COX-
2 correlated to loss of epithelial basement membrane
[49]. Additional studies are needed to establish the nature
of interactions between epithelial cells in inclusions cyst
and the surrounding basement membrane and stromal
environment. Furthermore, the co-expression of COX-1
and COX-2 in epithelial cells of inclusion cysts and B/BL
tumours, opens also the possibility fort an autocrine/para-
crine regulation of the two COX isoforms by PGE2.
The expression and regulation of mPGES-1 share many
similarities with that of COX-2, e.g. induced by pro-
inflammatory stimuli and hormones [50]. This is in con-
trast to the two other known members of this family,
mPGES-2 and cPGES, which are constitutively expressed
in various cells and tissues [50]. Both these isoforms are
functionally closer linked to COX-1, while mPGES-1 has
a marked preference to COX-2 [50]. Staining of the nor-
mal ovary for mPGES-1 revealed expression in the stroma,
while the OSE cells were mostly negative. This pattern was
also observed in the BL with some staining of epithelial
cells or cells associated to the epithelium. A significant
increase was observed in the AC, but not in B/BL. This
increase was correlated to grade, but not to stage. Intense
staining was demonstrated in a cluster-like pattern, pre-
dominantly in the tumour stroma. This might to some
extent reflect the presence of immune cells recruited to the
tumour site as a part of an inflammatory reaction. A local,
anti-inflammatory response to IL-1α was suggested [51]
to involve production of cortisol in the normal OSE by an
increase of 11β-HSD, while this enzyme was not
expressed in cell lines derived from EOC [52]. Infiltration
of macrophages into EOC was described by Klimp and co-
workers [53] and their study demonstrated increased lev-
els of COX-2 in tumour-associated macrophages. The role
of mPGES-1 for PGE2 production in these cells are essen-
tial since isolated peritoneal macrophages from mPGES-1
null mice produced minimal amounts of this prostanoids
in response to pro-inflammatory stimuli (LPS) [50]. Sim-
ilar results were obtained with macrophages from C/
EBPβ-deficient mice as a result of ablated mPGES-1
expression. This emphasise the role of inflammation in
EOC since C/EBPβ has been demonstrated to be major
regulator of pro-inflammatory genes, in addition to COX-
2 and mPGES-1 [50]. The cellular localization of mPGES-
1 in the present study, suggested a close connection to the
cells expressing EP1–2 receptors, which also support an
autocrine/paracrine regulatory pathway. An earlier study
[35] showed the content of mPGES-1 in ovarian cancer
cell lines, but the present study is the first, to our knowl-
edge, to demonstrate the expression of mPGES-1 in EOC.
Previous studies have demonstrated that PGE2  acted
mainly via the EP2 receptor in female reproduction and in
tumourigenesis, while EP1 was more involved in neuronal
functions [29]. Significant increases were found for the
expressions of both EP1  and EP2  in AC compared to
benign tumours in the present study. Interestingly, one of
the findings in the present study was a difference in the
distribution of EP-receptors between stroma and tumour
tissue. The majority of the EP1–2 immunoreativity was
found in OSE while only EP2 could be demonstrated in
the stroma. First, this suggests target cells for PGE2 in both
these cell compartments and secondly a separate function,
mediated by the EP2 receptor in the stroma. In addition,
the immunblotting experiment demonstrated multiple
bands for the two receptors. These bands could represent
phosphorylated forms of the receptors as well as splice
variants [29], and therefore have important implications
for cell signalling. The two receptors regulates different
intracellular signalling pathways, i.e. IP3/Ca2= (EP1) and
cAMP (EP2). Phosphorylated residues and splice variants
can potentially alter sensitivity, responsiveness and pre-
ferred signalling system within the cells [29], all of which
can contribute to enhanced tumour growth. However,
additional experiments are needed to explore these possi-
bilities.
Staining of cluster of cells in the AC, demonstrated for pri-
marily for mPGES-1 and EP1–2, were earlier reported for
both COX-1 and COX-2 [36]. Previous studies have actu-
ally localised COX enzymes to a large variety of cells,Molecular Cancer 2006, 5:62 http://www.molecular-cancer.com/content/5/1/62
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including both normal and tumour epithelial cells, nor-
mal and tumour vascular endothelium and smooth mus-
cle cells, macrophages and fibroblast cells. The clearly
defined staining of populations of malignant cells, found
here and by others, may implicate specific functions, such
as angiogenesis and invasion or a more active anti-tumour
response for mPGES-1 and EP1–2 in different populations
of the malignant cells. Cluster like expression of COX-2
was recently reported to correlate to angiogenesis in pros-
tate cancer [54].
Conclusion
In the present study, statistically significant increases, as
well as cell-specific localizations were demonstrated for
COX-1, COX-2 and mPGES-1 in adenocarcinomas com-
pared to the normal ovary and benign tumour tissue.
These elevations in malignant cells can be a response to an
inflammatory reaction, both chronic and acute, caused by
a growing and potentially invasive tumour, and the inter-
actions between tumor cells, stromal cells and the
immune system.
The increase of COXs, mPGES-1 and EP receptors in epi-
thelial ovarian tumours supports the hypothesis that
PGE2 is an important factor for progression (proliferation/
angiogenesis) in ovarian tumours. The appearance of
COX-2 in potential pre-malignant structures (inclusion
cysts) may indicate a role in malignant transformation of
epithelial cells, in addition to its earlier documented pres-
ence in malignant tumours. The results also suggest that
the synthesis of PGE2 is regulated by autocrine and para-
crine factors (i.e. cytokines) as a result of epithelial-stro-
mal interactions. Furthermore, mPGES-1 and the EP
receptors may represent important targets for develop-
ment of novel anti-inflammatory and anti-tumour thera-
pies.
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